从最新研究进展看低分子肝素与肝素的区别
操作说明:
·点击在线课件进行翻页操作。
·按键盘的“左”或“右”方向键进行翻页操作。(激活播放窗口的前提下)
·按键盘的“上”或“下”方向键切换到课件的开头或结尾。（同上）
·点击在线课件进行翻页操作。
·按键盘的“左”或“右”方向键进行翻页操作。(激活播放窗口的前提下)
·按键盘的“上”或“下”方向键切换到课件的开头或结尾。（同上）
用户评分 请客观打分
| 1分 |  |
0 |
| 2分 | |
0 |
| 3分 | |
0 |
| 4分 | |
2 |
| 5分 | |
10 |
共 163 人打分 | 平均 3.8 分
· 课件简介：This trial proved its primary hypothesis: Enoxaparin is noninferior to UH on the composite of death, MI, and refractory ischemia Trends in all composite clinical endpoints favored enoxaparin Trends toward enoxaparin benefit were greater in high-risk patients Results are consistent with trials not using background GP IIb/IIIa inhibition Combined bleeding (TIMI major + minor) did not differ significantly (p=0.093) between groups, although a trend favored UH for TIMI major bleeds Transfusion rates were low and not significantly different (p=0.405) between the two treatment arms
相关资讯
010-86459523 